Does the HPV vaccination programme have implications for cervical screening programmes in the UK?

被引:37
作者
Beer, Helen [1 ]
Hibbitts, Sam [2 ]
Brophy, Sinead [3 ]
Rahman, M. A. [3 ]
Waller, Jo [4 ,5 ]
Paranjothy, Shantini [2 ]
机构
[1] Cerv Screening Wales, Screening Div, Publ Hlth Wales, Cardiff CF11 9LJ, S Glam, Wales
[2] Cardiff Univ, Sch Med, Cardiff CF14 4XN, S Glam, Wales
[3] Swansea Univ, Coll Med, Hlth Informat Res Unit, Swansea SA2 8PP, W Glam, Wales
[4] UCL, Res Dept Epidemiol & Publ Hlth, Canc Res UK Hlth Behav Res Ctr, London WC1E 6BT, England
[5] Swansea Univ, Coll Med, Ctr Improvement Populat Hlth Erecords Res, Swansea SA2 8PP, W Glam, Wales
基金
英国惠康基金; 英国经济与社会研究理事会; 英国医学研究理事会;
关键词
HPV-16/18 AS04-ADJUVANTED VACCINE; PAPILLOMAVIRUS (HPV)-16/18 VACCINE; BLIND PATRICIA TRIAL; OF-STUDY ANALYSIS; AGED; 18-45; YEARS; HPV-6/11/16/18; VACCINE; YOUNG-WOMEN; ADULT WOMEN; FOLLOW-UP; EFFICACY;
D O I
10.1016/j.vaccine.2014.01.087
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the UK, a national HPV immunisation programme was implemented in 2008 for girls aged 12-13 years. In addition a catch-up programme was implemented for older girls up to 18 years of age from 2009 to 2011, with an uptake rate of 49.4%. Information about future uptake of cervical screening according to vaccination statistics is important in order to understand the impact of the vaccination programme and implications for a national cervical screening programme. We analysed data on a cohort of women who had been offered the HPV vaccine in the catch-up programme and were invited for cervical screening between 2010 and 2012 in Wales (n=30,882), in a record-linked database study, to describe the cervical screening uptake and clinical outcome according to HPV vaccination status. In our cohort, 48.5% (n=14,966) women had had HPV vaccination and 45.9% (n=14,164) women attended for cervical screening. Women who were unvaccinated were less likely to attend cervical screening (adjusted OR 0.58; 95% CI (0.55, 0.61)). Of those who attended for screening, 13.9% of vaccinated women had abnormal cytology reported compared to 16.7% of women who were unvaccinated. Women who lived in areas with high levels of social deprivation were less likely to be vaccinated (Quintile 5 OR 0.48 95% CI (0.45, 0.52)) or attend cervical screening (Quintile 5 OR 0.70; 95% CI (0.65, 0.75)) compared to those who lived in the least deprived areas. These data highlight the need for new strategies to address inequalities in cervical screening uptake and can inform further mathematical modelling work to clarify the impact of the HPV vaccination programme on future cervical cancer incidence. (c) 2014 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1828 / 1833
页数:6
相关论文
共 23 条
[1]  
[Anonymous], 1988, HLTH DEPRIVATION INE
[2]   Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England [J].
Bowyer, Harriet L. ;
Marlow, Laura A. V. ;
Hibbitts, Sam ;
Pollock, Kevin G. ;
Waller, Jo .
VACCINE, 2013, 31 (07) :1051-1056
[3]   End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age [J].
Castellsague, X. ;
Munoz, N. ;
Pitisuttithum, P. ;
Ferris, D. ;
Monsonego, J. ;
Ault, K. ;
Luna, J. ;
Myers, E. ;
Mallary, S. ;
Bautista, O. M. ;
Bryan, J. ;
Vuocolo, S. ;
Haupt, R. M. ;
Saah, A. .
BRITISH JOURNAL OF CANCER, 2011, 105 (01) :28-37
[4]   Elucidating the spatially varying relation between cervical cancer and socio-economic conditions in England [J].
Cheng, Edith M. Y. ;
Atkinson, Peter M. ;
Shahani, Arjan K. .
INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS, 2011, 10
[5]   Sustained efficacy and immunogenicity of the HPV-16/18 ASO4-adjuvanted vaccine up to 7.3 years in young adult women [J].
De Carvalho, N. ;
Teixeira, J. ;
Roteli-Martins, C. M. ;
Naud, P. ;
De Borba, P. ;
Zahaf, T. ;
Sanchez, N. ;
Schuind, A. .
VACCINE, 2010, 28 (38) :6247-6255
[6]   Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years [J].
Einstein, Mark H. ;
Baron, Mira ;
Levin, Myron J. ;
Chatterjee, Archana ;
Fox, Bradley ;
Scholar, Sofia ;
Rosen, Jeffrey ;
Chakhtoura, Nahida ;
Lebacq, Marie ;
van der Most, Robbert ;
Moris, Philippe ;
Giannini, Sandra L. ;
Schuind, Anne ;
Datta, Sanjoy K. ;
Descamps, Dominique .
HUMAN VACCINES, 2011, 7 (12) :1359-1373
[7]   Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years [J].
Einstein, Mark H. ;
Baron, Mira ;
Levin, Myron J. ;
Chatterjee, Archana ;
Fox, Bradley ;
Scholar, Sofia ;
Rosen, Jeffrey ;
Chakhtoura, Nahida ;
Meric, Dorothee ;
Dessy, Francis J. ;
Datta, Sanjoy K. ;
Descamps, Dominique ;
Dubin, Gary .
HUMAN VACCINES, 2011, 7 (12) :1343-1358
[8]  
Government WA, 2008, BIRTH WAL 2007 DAT N
[9]   HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine [J].
Joura, Elmar A. ;
Kjaer, Susanne K. ;
Wheeler, Cosette M. ;
Sigurdsson, Kristjan ;
Iversene, Ole-Erik ;
Hernandez-Avila, Mauricio ;
Perez, Gonzalo ;
Brown, Darron R. ;
Koutsky, Laura A. ;
Tay, Eng Hseon ;
Garcia, Patricia ;
Ault, Kevin A. ;
Garland, Suzanne M. ;
Leodolter, Sepp ;
Olssonn, Sven-Eric ;
Tang, Grace W. K. ;
Ferris, Daron G. ;
Paavonen, Jorma ;
Lehtinen, Matti ;
Steben, Marc ;
Bosch, Xavier ;
Dillner, Joakim ;
Kurmanv, Robert J. ;
Majewski, Slawomir ;
Munoz, Nubia ;
Myers, Evan R. ;
Villa, Luisa L. ;
Taddeo, Frank J. ;
Roberts, Christine ;
Tadesse, Amha ;
Bryan, Janine ;
Lupinaccia, Lisa C. ;
Giacoletti, Katherine E. D. ;
Lu, Shuang ;
Vuocolo, Scott ;
Hesley, Teresa M. ;
Haupt, Richard M. ;
Barr, Eliav .
VACCINE, 2008, 26 (52) :6844-6851
[10]   Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial [J].
Kreimer, Aimee R. ;
Gonzalez, Paula ;
Katki, Hormuzd A. ;
Porras, Carolina ;
Schiffman, Mark ;
Cecilia Rodriguez, Ana ;
Solomon, Diane ;
Jimenez, Silvia ;
Schiller, John T. ;
Lowy, Douglas R. ;
van Doorn, Leen-Jan ;
Struijk, Linda ;
Quint, Wim ;
Chen, Sabrina ;
Wacholder, Sholom ;
Hildesheim, Allan ;
Herrero, Rolando .
LANCET ONCOLOGY, 2011, 12 (09) :862-870